Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα-TRAF3-TAK1-MAPK axis.
Xie L, Xue F, Cheng C, Sui W, Zhang J, Meng L, Lu Y, Xiong W, Bu P, Xu F, Yu X, Xi B, Zhong L, Yang J, Zhang C, Zhang Y.
Xie L, et al. Among authors: zhong l.
Signal Transduct Target Ther. 2024 Oct 16;9(1):273. doi: 10.1038/s41392-024-01977-z.
Signal Transduct Target Ther. 2024.
PMID: 39406701